Preferred Label : Anti-CD73 Monoclonal Antibody HLX23;
NCIt definition : A recombinant, humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase
(cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential
immunomodulating and antineoplastic activities. Upon administration, anti-CD73 monoclonal
antibody HLX23 targets and binds to CD73 on tumor cells, thereby inhibiting the activity
of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate
(AMP) to adenosine and the adenosine-mediated suppression of lymphocyte activity and
trafficking. This increases the activity of cytotoxic T-lymphocytes (CTLs), activates
macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs)
and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune
system and enhancing the CTL-mediated immune response against cancer cells, tumor
cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase
(NTase) family, is upregulated on a number of cancer cell types and catalyzes the
conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides,
such as adenosine; it plays a key role in adenosine-mediated immunosuppression within
the tumor microenvironment (TME).;
Molecule name : HLX-23; HLX 23;
NCI Metathesaurus CUI : CL1662796;
Origin ID : C180375;
UMLS CUI : C5556327;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
